Bevacizumab biosimilar (Tanvex BioPharma)

贝伐珠单抗生物类似药 (泰福生技)

Report date: 2022/03/15 15:42:21

Base Information

Drug NameBevacizumab biosimilar (Tanvex BioPharma)

Drug Alias Name贝伐珠单抗生物仿制药 (Tanvex BioPharma)贝伐赛珠单抗生物仿制药 (Tanvex BioPharma)贝伐单抗生物仿制药 (Tanvex BioPharma)贝伐人源化单抗生物仿制药 (Tanvex BioPharma)TX-16

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

ATC CodeL01XC07